HURA · TuHURA Biosciences, Inc.

Track HURA — free

$2.01 -0.08 (-3.60%) At close · Oct 22

Rebalance outlook locked

Market Cap

$132.87M

63.73M

Volume · Oct 22 606.84K Avg daily vol (3M) 240.31K

Up next

Latest filing: 10-Q

filed Aug 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 122 metrics

Revenue (TTM)

Trailing 12 months

Net income (TTM)

−$30.62M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-22.5%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

−$2.60M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+43.6%

Year over year · more shares

Price change (1Y)

-10.7%

Trailing year

Short interest

9.6%

Latest settlement · 28.4 days to cover

View all 122 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 16.7 · calm Equity put/call 0.52

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +4%

above

Price vs 50-day avg −2%

below

RSI (14) 53

neutral

MACD trend Positive

52-week position 58%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return −4%

trailing

6-month return −14%

trailing

YTD return +166%

this year

Relative strength −20%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $2 › 200d $2 — 50d above 200d

Institutional flow Accumulating

14 of 89 funds reported for Sep 30 · net +71.9K sh shares · +2 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

9.57% of float · ▼ -2.9% MoM · 28.4 days cover

Volume signal Reversal watch

High volume on a down day — possible exhaustion

Institution breadth Multi-yr high

89 holders — near 3-yr high, broad support

Squeeze score 71

high risk · 0–100

Fundamentals

Strong

EPS growth +48%

Y/Y

Free cash flow $-27.7M

Balance sheet $3.7M

net cash

Quant / Vol

risk profile

Very High

Volatility 130%

annualized · 1-yr

Max drawdown −83%

past year

ATR 7.0%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy

0 · 5 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+4% Bullish

Price vs 50-day avg

−2% Neutral

RSI (14)

53 Neutral

MACD trend

Positive Bullish

52-week position

58% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $2 › 200d $2 — 50d above 200d

Institutional flow Accumulating

14 of 89 funds reported for Sep 30 · net +71.9K sh shares · +2 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

9.57% of float · ▼ -2.9% MoM · 28.4 days cover

Volume signal Reversal watch

High volume on a down day — possible exhaustion

Institution breadth Multi-yr high

89 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $0 Now $2 · 58% Range high $3

vs 200-day avg +4% vs 50-day avg -2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
HURA TuHURA Biosciences, Inc. this stock	$132.87M	+165.5%	—	—	9.6%
VRTX Vertex Pharmaceuticals Inc	$136.14B	+18.0%	+46.2%	31.3	1.8%
MRNA Moderna, Inc.	$98.14B	+587.1%	+4.3%	—	7.7%
REGN Regeneron Pharmaceuticals, Inc.	$82.95B	+6.1%	+20.8%	20.0	2.1%
CSLLY Csl Ltd	$65.88B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

% held: 14.2%
Reported: 14 of 89
Top holder: VANGUARD CAPITAL MANAGEME…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

6.1M

Days to cover: 28.4d
Change: -183.5K sh

View

Short Volume

Short vol %

59%

As of: Oct 22, 2026

Short Total

View

Fails to Deliver

FTD shares

20.1K

Value: $42.1K
As of: Sep 29, 2026

View

Off-Exchange

Off-exchange %

30.4%

Week of: Sep 14, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Buy

Member

Laurel Lee

Amount: $50.0K–$100.0K
Traded: Jul 13, 2025

View

Financials

Revenue (FY)

Net income (FY): $-30.1M
EPS diluted: $-0.63

View

Filings

SEC Filings

Latest

8-K

Filed: Oct 16, 2026
This year: 29

On October 9, 2026, TuHURA Biosciences, Inc. borrowed an additional $650,000 under its $50 million revolving credit facility with Parkview Holdings One LLC, which matures April 21, 2031; funds will support general corporate purposes.

View

Exempt Offerings

Offering

$3.0M

Filed: Nov 10, 2025

View

Earnings & Events

Webcasts

Last webcast

Aug 12, 2026

View

Performance

	5D	20D	120D	MTD	YTD
HURA	+9.8%	-4.3%	-13.7%	-4.3%	+165.5%
SPY	-1.0%	-0.4%	+6.0%	+0.2%	+12.0%
vs SPY	+10.9%	-3.9%	-19.7%	-4.5%	+153.5%

Key facts CIK 1498382 CUSIP 898920103 13F (30d) 11 filings 11 filers Visit website Investor relations

HURA · TuHURA Biosciences, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance